New molecular insights occasionally lead to the rapid development of therapeutic agents that improve the outcomes of patients with cancer; however, these breakthroughs can be followed by extensive, empirically driven and often unsuccessful efforts at extending the drug to other indications or combinations. Herein, we describe the clinical development of imatinib, a paradigm of rapid molecularly driven drug development, and advocate for a balanced portrayal of the potential of molecularly targeted therapies for cancer.
This is a preview of subscription content, log in via an institution to check access.
References
TIME. Drugs that fight cancer. TIME http://content.time.com/time/covers/0,16641,20010528,00.html (2001).
Cohen, M. H. et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 8, 935–942 (2002).
FDA. Drugs@FDA: FDA approved drug products. FDA https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588 (2018).
Yam, C. et al. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β. Invest. New Drugs 36, 1103–1109 (2018).
Carlisle, B. G. et al. Patient benefit and risk in anticancer drug development: a systematic review of the ixabepilone trial portfolio. medRxiv https://www.medrxiv.org/content/10.1101/19003467v1 (2019).
Boyiadzis, M. M. et al. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J. Immunother. Cancer 6, 35 (2018).
Walker, I. & Newell, H. Do molecularly targeted agents in oncology have reduced attrition rates? Nat. Rev. Drug Discov. 8, 15–16 (2008).
Hey, S. P., Heilig, C. M. & Weijer, C. Accumulating Evidence and Research Organization (AERO) model: a new tool for representing, analyzing, and planning a translational research program. Trials 14, 1 (2013).
Acknowledgements
The work of J.K. is funded by the Canadian Institutes of Health Research (CIHR; EOG111391). Without in any way implying endorsement of the contents of this article, the authors thank members of STREAM and H. Atkins for helpful consultations.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Carlisle, B.G., Zheng, T. & Kimmelman, J. Imatinib and the long tail of targeted drug development. Nat Rev Clin Oncol 17, 1–3 (2020). https://doi.org/10.1038/s41571-019-0287-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-019-0287-0
- Springer Nature Limited
This article is cited by
-
Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Lenvatinib Clinical Trials: A Systematic Review
Targeted Oncology (2024)
-
A novel strategy to bind pyrimidine sulfonamide derivatives with odd even chains: exploration of their design, synthesis and biological activity evaluation
Molecular Diversity (2023)
-
Quantifying Patient Investment in Novel Neurological Drug Development
Neurotherapeutics (2022)